The RNA Based Therapeutics and Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region.
Several new & existing DNA-editing companies have declared their ambition to expand into the RNA segment, and these include Boston, Massachusetts-based Beam Therapeutics, which has been researching CRISPR DNA editing as a treatment for several blood disorders. San Diego-based firm named Locana is also studying CRISPR-based RNA editing as a potential treatment for diseases like Huntington's disease and motor-neuron disorder.
CRISPR-based RNA Editing to Offer Lucrative Growth Prospects
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) is an RNA-guided gene editing technique that inserts a double-strand break at a specific site in the genome using the Cas9 protein, which is obtained from bacteria. By using this technique, bacteria are able to seize brief nucleic acid sequences from invasive pathogens and mix them with the repeats in CRISPR loci. A group of bacterial endonucleases is directed by small RNAs generated by transcription of CRISPR loci to divide the genomes of invasive pathogens. This approach has gained acceptance as a potent method that makes genome editing possible in everyday lifeSeveral new & existing DNA-editing companies have declared their ambition to expand into the RNA segment, and these include Boston, Massachusetts-based Beam Therapeutics, which has been researching CRISPR DNA editing as a treatment for several blood disorders. San Diego-based firm named Locana is also studying CRISPR-based RNA editing as a potential treatment for diseases like Huntington's disease and motor-neuron disorder.
Numerous Development Potential of RNA-based Medicines
Since RNA-based therapies have the potential to cure both common and rare genetic illnesses, RNA-based therapies have attracted a lot of research. These types of studies are still in the pipeline, therefore businesses that commercialise these treatments first would have a competitive advantage over rivals. There are now just three commercially available RNA-based medicines based on antisense technology. Three ASO medicines have so far been approved by the FDA: nusinersen (Ionis Pharmaceuticals), eteplirsen (Sarepta Therapeutics), and inotersen (Ionis Pharmaceuticals and Akcea Therapeutics). As a result, there are numerous potential for the development and marketing of RNA-based medicines in the near future.What Questions Should You Ask before Buying a Market Research Report?
- How is the RNA therapeutics market evolving?
- What is driving and restraining the RNA therapeutics market?
- How will each RNA therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each RNA therapeutics submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading RNA therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the RNA therapeutics projects for these leading companies?
- How will the industry evolve during the period between 2022 and 2032? What are the implications of
- Is there a greater need for product commercialization to further scale the RNA therapeutics market?
- Where is the RNA therapeutics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the RNA therapeutics market today, and over the next 10 years:
- Our 223-page report provides 96 tables and 146 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
Segments Covered in the Report
Type
- RNA Antisense Technologies
- RNA Interference (RNAi) Technologies
Application
- Genetic Disorders
- Spinal Muscular Atrophy (SMA)
- Cancer
- Acute Hepatic Porphyria (AHP)
- Duchenne Muscular Dystrophy (DMD)
- Others
- Autoimmune Disorders
- Ophthalmology
- Oncology
- Diabetes
- Rheumatoid Arthritis (RA)
- Others
End-user
- Research Institutes
- Hospitals & Clinics
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies and the potential for market growth
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma
- Biogen
- Genzyme (Sanofi)
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Orna Therapeutics
- Sarepta Therapeutics, Inc.
- Silence Therapeutics
How will the RNA Therapeutics Market, 2022 to 2032 report help you?
In summary, this 210+ page report provides you with the following knowledge:- Revenue forecasts to 2032 for RNA Therapeutics Market, 2022 to 2032 Market, with forecasts for type, application, and end-user each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for five regional and 20 key national markets - See forecasts for the RNA Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the RNA Therapeutics Market, 2022 to 2032.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the RNA Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 RNA Therapeutics Market Analysis by Technology
5 RNA Therapeutics Market Analysis by Application
6 RNA Therapeutics Market Analysis by End-user
7 RNA Therapeutics Market Analysis by Region
8 North America RNA Therapeutics Market Analysis
9 Europe RNA Therapeutics Market Analysis
10 Asia Pacific RNA Therapeutics Market Analysis
11 Latin America RNA Therapeutics Market Analysis
12 MEA RNA Therapeutics Market Analysis
13 Company Profiles
14 Conclusion and Recommendations
Companies Mentioned
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma
- Biogen
- Genzyme (Sanofi)
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Orna Therapeutics
- Sarepta Therapeutics, Inc.
- Silence Therapeutics
- AGC Biologics
- Beam Therapeutics
- Boehringer Ingelheim
- CRISPR Therapeutics
- Curia
- Delphi Genetics
- Eurofins Genomics
- Fujifilm Diosynth Biotechnologies
- Hanmi Pharmaceutical Group
- Intellia Therapeutics
- Lonza
- Precision Nanosystems
- Regeneron
- Samsung Biologics
- Sigma Aldrich
- Thermo Fisher Scientific Inc.
- VIVEbiotech
- Wuxi Apptec
- Biomedical Advanced Research and Development Authority (BARDA)
- Centers for Disease Control and Prevention (CDC)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Committee for Medicinal Products for Human Use (CHMP)
- European Commission (EC)
- European Medicines Agency (EMA)
- Food and Drug Administration (FDA)
- GAVI
- Haute Autorité de santé (HAS)
- Indian Council of Medical Research (ICMR)
- International AIDS Vaccine Initiative (IAVI)
- King Abdulaziz University (KAU)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- National Health Service (NHS)
- National Institute of Virology (NIV)
- Russian Direct Investment Fund (RDIF)
- Servizio Sanitario Nazionale (SSN)
- United Nations Children's Fund (UNICEF)
- University of Saskatchewan (USask, Canada)
- University of Zaragoza
- US Department of Health and Human Services (HHS)
- Vaccine and Infectious Disease Organization (VIDO)
- World Health Organization (WHO)